The clinical relevance of B-type natriuretic peptide (BNP) as a diagnostic tool and prognostic marker in patients with cardiovascular diseases has been confirmed recently (1) (2) (3) . Over the last 5 years, several immunoassay methods for the measurement of BNP, which share some analytical characteristics, such as full automation, turnaround time Ͻ60 min, lower imprecision, and/or better analytical and functional sensitivity, have become commercially available (1, 4 ) . The analytical performance and diagnostic accuracy of immunoassays for BNP were compared recently (5, 6 ) . In the present study, we evaluated the analytical performance and diagnostic accuracy of an automated immunochemiluminescent assay for BNP (ACCESS System; Beckman Coulter). We also compared its performance and accuracy with the TRIAGE BNP test (Biosite). The 2 immunoassays use as antigen the intact BNP 1-32 peptide and the same mouse anti-human BNP antibodies. The capture antibody (Scios) recognizes the peptide ring, whereas the detection antibody (Biosite) recognizes an epitope between amino acids 5 and 10 at the NH 2 terminus (6, 7 ). All statistical analyses were performed by use of parametric tests after log transformation of the original data. Nonparametric tests were also performed and showed identical statistical trends.
We collected blood samples from 91 healthy individuals [51 women and 40 men; mean (SD) age, 43.2 (13.4) years; range, 16 -71 years] and 214 patients with idiopathic or secondary cardiomyopathy (only 21 with a left ventricular ejection fraction Ͼ50%). Blood was collected between 0800 and 0900 after the individuals had fasted overnight and had rested for 20 min in a supine position. Immediately after withdrawal, blood samples (8 -10 mL) were placed in ice-chilled disposable polypropylene tubes containing EDTA (1 mg/mL of plasma). Plasma samples were obtained shortly after venipuncture by centrifugation for 15 min at 4°C and then were frozen and stored at Ϫ20°C in 0.5-mL aliquots until being assayed.
We found that plasma samples can be kept at 37°C for We confirmed the results of a previous study from our laboratory indicating that the detection limit of the TRIAGE is Ͻ8 ng/L (manufacturer-reported detection limit, 5 ng/L) (8 ) . The imprecision profiles of the TRIAGE and ACCESS, obtained by repeated measurements over 20 different days of several plasma samples (7 on the TRIAGE and 12 on the ACCESS) with BNP concentrations covering the analytical working range, are shown in Fig.  1A . According to the IFCC goals for desirable (15% total CV) and optimum (10% total CV) imprecision (7 ), the 2 methods had similar functional sensitivities (ϳ10 ng/L and 30 ng/L, respectively). The imprecision for samples with BNP values Ͻ10 ng/L was not satisfactory in either method. We assessed the within-run and total imprecision of the ACCESS according to the NCCLS EP5-A guideline (including experimental protocol, number of measurements, and data calculation) (9 ) by repeatedly assaying 2 plasma samples with BNP concentrations of 52.6 and 1095 ng/L in duplicate on 20 different working days (both in the morning and in the afternoon). For the 2 samples, within-run imprecision was 3.4% and 1.6%, respectively, and total imprecision was 8.4% and 5.9%.
After exclusion by statistical analysis of the 17 samples with BNP values Ͻ5 ng/L in the TRIAGE assay, we found a close linear relationship (R ϭ 0.919; n ϭ 287) between the 2 methods: ACCESS ϭ 62.5 (14.1) ϩ 0.932 (0.024) TRIAGE (P Ͻ0.0001 for both). The Bland-Altman plot of the same data confirmed that there was a difference between the values measured with the 2 immunoassays; this difference increased proportionally as the measured concentration increased (Fig. 1B) (10 ) . There was a slight but significant mean difference between the values [mean (SD) difference for TRIAGE Ϫ ACCESS, Ϫ45.2 (217.8) ng/L (minimummaximum, Ϫ1152 to 1667 ng/L; P Ͻ0.0001); mean % difference, Ϫ0.2% (minimum-maximum, Ϫ2.0% to 1.7%)].
All 91 healthy persons were nonobese, normotensive, and free from acute or chronic diseases. Moreover, all had values within the reference intervals for creatinine, urea, glucose, uric acid, albumin, electrolytes, cardiac markers, and hemoglobin as well as for erythrocyte and leukocyte Fig. 1 of the Data Supplement that accompanies this Technical Brief at http://www. clinchem.org/content/vol51/issue7/.
To evaluate the diagnostic accuracy of the 2 methods, we measured only samples from the 193 patients with a clinically ascertained diagnosis of heart failure. The clinical characteristics of these patients are reported in Table 1 . Cardiac morphology and function were assessed by 2-dimensional echocardiography, or cardiac catheterization when needed. The median (range) ACCESS and TRIAGE BNP concentrations measured were 171 (2-4833) ng/L and 118 (Ͻ5 to 4930) ng/L, respectively. The distributions of BNP values measured by the 2 methods in these patients grouped according to the severity of heart failure [New York Heart Association (NYHA) functional classes I to IV] are shown in Figs. 1 and 2 of the online Data Supplement. However, the results obtained with both the TRIAGE and ACCESS indicated a significant difference between the mean BNP values in healthy persons vs heart failure patients (P Ͻ0.0001 by Scheffè test after ANOVA).
We used ROC curve analysis to evaluate the diagnostic accuracy of the 2 methods in differentiating between healthy persons and patients with heart failure. We found no difference in diagnostic accuracy between the 2 methods for differentiating healthy persons from patients with mild (NYHA class I and II; n ϭ 122; P ϭ 0.196) or severe (NYHA class III and IV; n ϭ 71; P ϭ 0.697) heart failure. For the TRIAGE, the areas under the curves were 0.840 (SE, 0.027; 95% CI, 0.788 -0.893) for patients with mild disease and 0.998 (SE, 0.002; 95% CI, 0.995-1.000) for patients with severe heart failure, whereas for the ACCESS system, the areas under the curves were 0.870 (SE, 0.023; 95% CI, 0.825-0.916) for patients with mild disease and 0.997 (SE, 0.002; 95% CI, 0.993-1.000) for patients with severe heart failure. The BNP values corresponding to a sensitivity of 95% in differentiating healthy persons from patients with mild heart failure were 7.5 ng/L (corresponding specificity, 40%) for the ACCESS and 5.1 ng/L for the TRIAGE (corresponding specificity, 29%). The BNP values corresponding to a specificity of 95% were 41 ng/L (corresponding sensitivity, 65%) for the ACCESS and 29 ng/L (corresponding sensitivity, 63%) for the TRIAGE (Fig. 3 of the online Data Supplement). However, it is important to emphasize that the 95% sensitivity with the TRIAGE was obtained at a cutoff near the assay detection limit. The decision cutoff values from the current study are strictly related to our specific clinical setting, comparing healthy persons and patients with clinically ascertained heart failure. In routine clinical practice, several groups of individuals/patients suspected of having a specific disease are usually compared.
The present data confirm and extend previous results suggesting that BNP results are method dependent and that a single predefined common cutoff value cannot be used (5, 6) . Furthermore, we demonstrated that immunoassays that use the same antibodies and calibration materials do not automatically give the same results. However, the cutoff and reference values of these 2 methods are similar.
